- Home
- NRT vs RNXT Comparison
NRT vs RNXT Comparison
Compare NRT & RNXT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- NRT
- RNXT
- Stock Information
- Founded
- NRT 1975
- RNXT 2012
- Country
- NRT United States
- RNXT United States
- Employees
- NRT N/A
- RNXT N/A
- Industry
- NRT Oil & Gas Production
- RNXT Biotechnology: Pharmaceutical Preparations
- Sector
- NRT Energy
- RNXT Health Care
- Exchange
- NRT Nasdaq
- RNXT Nasdaq
- Market Cap
- NRT 46.4M
- RNXT 44.6M
- IPO Year
- NRT N/A
- RNXT 2021
- Fundamental
- Price
- NRT $5.17
- RNXT $1.26
- Analyst Decision
- NRT
- RNXT Strong Buy
- Analyst Count
- NRT 0
- RNXT 2
- Target Price
- NRT N/A
- RNXT $7.50
- AVG Volume (30 Days)
- NRT 40.7K
- RNXT 648.4K
- Earning Date
- NRT 08-29-2025
- RNXT 11-12-2025
- Dividend Yield
- NRT 9.28%
- RNXT N/A
- EPS Growth
- NRT 24.05
- RNXT N/A
- EPS
- NRT 0.59
- RNXT N/A
- Revenue
- NRT $6,184,173.00
- RNXT $662,000.00
- Revenue This Year
- NRT N/A
- RNXT $2,895.35
- Revenue Next Year
- NRT N/A
- RNXT $313.04
- P/E Ratio
- NRT $8.88
- RNXT N/A
- Revenue Growth
- NRT 18.55
- RNXT N/A
- 52 Week Low
- NRT $3.88
- RNXT $0.75
- 52 Week High
- NRT $5.75
- RNXT $1.69
- Technical
- Relative Strength Index (RSI)
- NRT 47.79
- RNXT 58.65
- Support Level
- NRT $4.90
- RNXT $1.19
- Resistance Level
- NRT $5.39
- RNXT $1.45
- Average True Range (ATR)
- NRT 0.16
- RNXT 0.12
- MACD
- NRT 0.00
- RNXT 0.02
- Stochastic Oscillator
- NRT 55.10
- RNXT 62.75
About NRT North European Oil Royality Trust
North European Oil Royalty Trust holds overriding royalty rights covering gas and oil production in certain concessions or leases in the Federal Republic of Germany. The properties of the trust are overriding royalty rights on sales of gas, sulfur, and oil under certain concessions or leases in the Federal Republic of Germany. The trust also holds other royalty rights, which are based on leases. It receives various percentages of royalties on the proceeds of the sales of certain products from the areas involved.
About RNXT RenovoRx Inc.
RenovoRx Inc is a clinical-stage biopharmaceutical company developing proprietary targeted combination therapies for high unmet medical need with a goal to improve therapeutic outcomes for cancer patients undergoing treatment. RenovoRx's patented Trans-Arterial Micro-Perfusion therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy's toxicities versus systemic intravenous therapy.